Adults with Recurrent Glioblastoma (GBM) are Invited to Participate in a Research Study

The UVA Cancer Center is enrolling patients diagnosed with recurrent glioblastoma (GBM), a type of brain tumor, to participate in a clinical research study. Patients with this type of cancer usually undergo traditional care options including any combination of surgery, radiation, chemotherapy, or receipt of supportive care to help with symptoms.

A randomized, double-blind, multicenter, Phase 3 study to evaluate efficacy and safety of belumosudil in combination with corticosteroids versus placebo in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease (cGVHD)

The University of Virginia Comprehensive Cancer Center seeks participants ages 18 and over with a moderate or severe chronic graft versus host disease (cGVHD) that have not received any prior systemic treatment for cGVHD. The purpose of the study is to evaluate the efficacy and safety of belumosudil together with a corticosteroid (prednisone or prednisolone) versus placebo together with a corticosteroid (prednisone or prednisolone). Belumosudil is an oral medicine that regulates the immune reactions caused by the donor cells derived from the transplant.

Phase II study of adagrasib + stereotactic radiosurgery (SRS) for patients with metastatic KRAS G12C-mutated NSCLC with untreated brain metastases (LUN23-618)

The University of Virginia Cancer Center is conducting a clinical research study for patients who are adults ages 18 and over, and have metastatic KRAS G12C-mutated non-small cell lung cancer with brain metastases. The purpose of this study is to evaluate an investigational drug, adagrasib in combination with stereotactic radiosurgery. The safety and effects of the investigational treatment will be assessed for this study.

First-in-human, Phase 1a/1b trial to investigate BGB-3245 in Patients with Advanced or Refractory Tumors

The University of Virginia is conducting a clinical research study for adults ages 18 and over who have advanced or refractory tumors. The purpose of this study is to learn how well BGB-3245 works and collect safety information. BGB-3245 is being studied as a possible treatment for cancers that are growing quickly or have not stopped growing despite current treatment. You will be assigned to 1 of 2 groups based on your tumor status:

Randomized Phase 2 Study of daunorubicin and cytarabine liposome + Pomalidomide versus daunorubicin and cytarabine liposome in Newly Diagnosed AML with MDS-Related Changes

The University of Virginia is participating in a clinical research study for adults ages 18 and over, who have acute myeloid leukemia with myelodysplastic syndrome-related changes or acute myeloid leukemia after previous chemotherapy or radiation treatment. This study is being done to answer the following questions:
• Can we lower the chances of your acute myeloid leukemia (AML) growing by adding pomalidomide, to daunorubicin and cytarabine liposome therapy which is one of the standard treatment most people get for AML?

A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

The University of Virginia seeks adults ages 18 and over with Advanced Ovarian, Fallopian, or Peritoneal Cancer for a research study. You will be eligible if you have Low-Grade Serous Ovarian Cancer or LGSOC (ovarian, fallopian, peritoneal).

A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of an Anti-CD20 X Anti-CD3 BiSpecific Antibody, Versus Investigator’s Choice in Previously Untreated Participants with Follicular Lymphoma (OLYMPIA-1)

The University of Virginia is conducting a clinical research study for adults ages 18 and over with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma or NHL). The study is researching a study drug. Please note that this clinical trial will use an investigational drug product, the safety and efficacy of which has not been fully evaluated by Regulatory Authorities and which has not received marketing authorization in any country. This study will be made up of two parts: Part 1 and Part 2. The aim of Part 1 of the study is to see how tolerable the study drug is.

A Phase 2 Study of Darolutamide in Combination with Leuprolide Acetate in Hormone-Therapy Naïve Recurrent and/ or Metastatic Androgen Receptor (AR) Positive Salivary Gland Cancer

The University of Virginia is conducting a clinical research study for adults ages 18 and over who have salivary gland cancer that has spread, cannot be removed, or has come back, and has a protein called the AR (androgen receptor). The purpose of this study is to test the effects of a combination of drugs called darolutamide and leuprolide acetate and whether or not it could shrink your cancer. Daraolutamide and leuprolide acetate have already been approved by the FDA to treat other cancers, but this drug combination is not approved by the FDA for treatment of your disease.

CDT seeking individuals with Type 2 Diabetes who are 18 years or older for a clinical research study

Setting basal insulin parameters typically takes several weeks and requires frequent calls with your treating physician. The purpose of this study is to see if using an insulin pump could assist, and potentially accelerate, identifying the correct basal rates for you to better manage your type 2 diabetes. This is a randomized study so you will not get to choose which group you are assigned to. This is a randomized study so you will not get to choose which group you are assigned to.

Subscribe to